Management of Drug-Resistant Chronic Hepatitis B

Clinics in Liver Disease

Volumn 10, Issue 2, 2006, Pages 275-302

  Fung, Scott K ^a   Fontana, Robert J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; CLEVUDINE; EMTRICITABINE; ENTECAVIR; FAMCICLOVIR; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR;

ANTIBIOTIC RESISTANCE; CHRONIC HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL; CROSS RESISTANCE; CYTOPENIA; FLU LIKE SYNDROME; GENE LOCUS; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; MENTAL DISEASE; NEPHROTOXICITY; PATIENT MONITORING; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; PREDICTION; REVIEW; SYMPTOM; VIREMIA; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN;

BIOLOGICAL RESPONSE MODIFIERS; DRUG RESISTANCE, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INCIDENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33846199258     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2006.05.004     Document Type: Review

References (116)

1. Lee W.M. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med 350 (2004) 1118-1129
2. Chao S., Le P.V., Prapong W., et al. High prevalence of chronic hepatitis B (HBV) infection in Chinese Americans living in California. [abstract]. Hepatology 40 Suppl 1 (2004) 717
3. Sherman A., Tsang T., Villaneuva G., et al. Mass screenings in New York City reveal extraordinarily high prevalence of hepatitis B in an urban Asian population. [abstract]. Hepatology 41 Suppl 1 (2005) 47
4. McQuillan G.M., Coleman P.J., Kruszon-Moran D., et al. Prevalence of hepatitis B virus infection in the United States: The National Health and Nutrition Examination surveys 1976 to 1994. Am J Public Health 89 (1999) 14-18
5. Manno M., Camma C., Schepis F., et al. Natural history of chronic HBV carriers in Northern Italy: morbidity and mortality after 30 years. Gastroenterology 127 (2004) 756-763
6. Villeneuve J.P., Desrochers M., Infante-Rivard C., et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen positive carriers in Montreal. Gastroenterology 106 (1994) 1000-1005
7. Beasley R.P. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer 61 (1988) 1942-1956
8. Fattovich G., Giustina G., Schalm S.W., et al. Occurrence of hepatocellular carcinoma and decompensation in Western patients with cirrhosis type B. The EUROHEP Study Group on hepatitis B virus and cirrhosis. Hepatology 21 (1995) 77-82
9. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 23 (2003) 47-58
10. Liaw Y.F., Tai D.I., Chu C.M., et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8 (1988) 493-496
11. Yu M.W., Yeh S.H., Chen P.J., et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study. J Natl Cancer Inst 97 (2005) 265-272
12. Chen C.J., Yang H.E., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
13. Lok A.S.F., and McMahon B. American Association for the Study of Liver Diseases practice guidelines: chronic hepatitis B. Hepatology 39 (2004) 857-861
14. Fung S.K., and Lok A. Treatment of chronic hepatitis B: who to treat, what to use, and for how long?. Clin Gastroenterol Hepatol 2 (2004) 839-848
15. Weissberg J.L., Andres L.L., Smith C.I., et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 101 (1984) 613-616
16. Dejongh F.E., Janssen H.L., DeMan R.A., et al. Survival and prognostic factors in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 103 (1992) 1630-1635
17. Yuen M.F., Sabio E., Yuan H.J., et al. Relationship between the development of precore and corepromoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis 186 (2002) 1335-1338
18. Tur-Kaspa R., Shaul Y., Moore D.D., et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 167 (1988) 630-633
19. McMillan J.S., Shaw T., Angus P.W., et al. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 22 (1995) 36-43
20. Fattovich G., Giustain G., Christensen E., et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 46 (2000) 420-426
21. Liaw Y.F. Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 22 (1995) 1101-1108
22. Joshi B.S., Guindi M., and Heathcote E.J. BMI is an independent predictor of disease progression in patients with chronic hepatitis B. [abstract]. Hepatology 40 (2004) A995
23. Wai C.T., and Fontana R.J. Clinical significance of HBV genotypes, variants, and mutants. Clin Liver Dis 8 2 (2004) 321-352
24. Yuen M.F., Yuan H.J., Wong D.K.H., et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 54 (2005) 1610-1614
25. Liaw Y.F., Leung N.W., Guan R., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 25 (2005) 472-489
26. International European Association for the Study of the Liver. Consensus conference on hepatitis B: consensus statement. J Hepatol 38 (2003) S90-S103
27. Chien R.N., and Liaw Y.F. Atkins M and the Asian Hepatitis LamivudineTrial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 30 (1999) 770-774
28. Fontana R.J. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis 23 (2003) 89-100
29. Fung S.K., and Lok A.S.F. Management of patients with hepatitis B virus-induced cirrhosis. J Hepatol 42 (2005) S54-S64
30. Lau G.K.K., He M.L., Fong D.Y.T., et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36 (2002) 702-709
31. Lau G.K.K., Yiu H.H.Y., Fong D.Y.T., et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125 (2003) 1742-1749
32. Fung S.K., Wong F., Hussain M., et al. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat 11 (2004) 432-438
33. Werle-Lapostolle B., Bowden S., Locarnini S., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126 (2004) 1748-1758
34. Pawlotsky J. Molecular diagnosis of viral hepatitis. Gastroenterology 122 (2003) 1554-1568
35. Mommeja-Marin H., Mondou E., Blum R., et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 37 (2003) 1309-1319
36. Locarnini S., McMillan J., and Bartholomeusz A. The hepatitis B virus and common mutants. Semin Liver Dis 23 (2003) 5-20
37. Lok A., Heathcote J., and Hoofnagle J. Management of hepatitis B 2000: summary of a workshop. Gastroenterology 120 (2001) 1828-1853
38. Hussain M., and Lok A. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. J Viral Hepat 6 (1999) 183-194
39. Chu C.M., Chiu C.T., Sheen I.S., et al. Precore mutant of hepatitis B virus prevails in acute and chronic infections in an area in which hepatitis B is endemic. J Clin Microbiol 34 (1996) 1815-1818
40. Grandjacques C., Paradat P., Stuyver L., et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 33 (2000) 430-439
41. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 24 (2004) 3-10
42. Allen M.I., Deslauriers M., Andrews C.W., et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27 (1998) 1670-1677
43. Ogata N., Fuji K., Takigawa S., et al. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. J Med Virol 59 (1999) 270-276
44. Bock C., Tillmann H., Torresi J., et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122 (2002) 264-273
45. Marcellin P., Lau G.K.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
46. Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
47. Chang T.T., Gish R., de Man R., et al. Entecavir is superior to lamivudine for the treatment of HBeAg + chronic hepatitis B: results of a phase III study in nucleoside naive patients. [abstract]. Hepatology 40 (2004) 70
48. Shouval D., Lai C.L., Cheinquer H., et al. Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naïve HBeAg-chronic hepatitis B. [abstract]. Hepatology 40 Suppl 1 (2004) 728
49. Dienstag J., Schiff E., Wright T., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
50. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
51. Hadziyannis S.T., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
52. Lok A.S.F., Zoulim F., Locarnini S., et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J Clin Microbiol 40 (2002) 3729-3734
53. Locarnini S., Hotzakis A., Heathcote J., et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9 (2004) 679-693
54. Lok A.S.F., Lai C.L., Leung N., et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125 (2003) 1714-1722
55. Thibault V., Aubron-Oliver C., Agut H., et al. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 16 (2002) 131-133
56. Liaw Y.F., Chien R.N., Yeh C.T., et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30 (1999) 567-572
57. Liaw Y.V., Leung N.W., Chang T.T., et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119 (2000) 172-180
58. Dienstag J., Goldin R., Heathcote E.J., et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 124 (2003) 105-117
59. Liaw Y.F., Chien R.N., and Yeh C.T. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 9 (2004) 257-262
60. Chen C.H., Lee C.M., Lu S.N., et al. Comparison of clinical outcome between patients with and without continuing lamivudine therapy after biochemical breakthrough of YMDD mutants. J Hepatol 41 (2004) 454-461
61. Liaw Y.F., Sung J.J.Y., Chow W.C., et al. Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-31w
62. Sung JJY, Liaw YF, Farrell G, et al. Baseline factors affecting disease progression in chronic hepatitis B patients and advanced fibrosis or cirrhosis. Proceedings of the Asian Pacific Association for the Study of the Liver.
63. Andreone P., Gramenzi A., Cursaro C., et al. High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing lamivudine resistance. J Viral Hepat 11 (2004) 439-442
64. Mutimer D., Pillay D., Dragon E., et al. High pretreatment serum hepatitis B after titer predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 30 (1999) 715-721
65. Torresi J., Earnest-Silveira L., Deliyannis G., et al. Vaccine-induced anti-HBs escape mutants of hepatitis B virus arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology 293 (2002) 305-313
66. Fontana R.J., Hann H.W., Wright T., et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 7 (2001) 504-510
67. Schiff E.R., Lai C.L., Hadziyannis S., et al. Adefovir dipivoxil therapy for lamivudine resistant hepatitis B in pre and post liver transplantation patients. Hepatology 38 (2003) 1419-1427
68. Guan R., Lai C.L., Liaw Y.F., et al. Efficacy and safety of 5 years of lamivudine treatment of Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 16 Suppl 1 (2001) A60
69. Lai C.L., Dienstag J., Schiff E., et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36 (2003) 687-696
70. Yuen M.F., Sablon E., Hui C.K., et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 34 (2001) 785-791
71. Izzedine H., Hulot J.S., Launay-Vacher V., et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 66 (2004) 1153-1158
72. Hadziyannis S., Tassopoulos N.C., Heathcote E.J., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352 (2005) 2673-2681
73. Westland C.E., Yang H., Delaney W.E., et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 38 (2003) 96-103
74. Hadziyannis S., Tassopoulos N., Chang T., et al. Long-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HB e antigen negative chronic hepatitis B: results after 5 years of therapy. [abstract]. Hepatology 42 Suppl 1 (2005) 754
75. Fung S.K., Chae H.B., Fontana R., et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44 (2006) 283-290
76. Lee Y.S., Suh D.J., Lim Y.S., et al. Emergence of rtA181V/T and rtN236T mutations after 48 weeks of adefovir dipivoxil therapy in patients with lamivudine-resistant chronic hepatitis B. [abstract]. Hepatology 42 Suppl 1 (2005) A578
77. Angus P., Vaughan R., Xiong S., et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125 (2003) 292-297
78. Bartholomeusz A., Locarnini S., Ayers A., et al. Molecular modeling of hepatitis B virus polymerase and adefovir resistance identifies three clusters of mutations. [abstract]. Hepatology 40 Suppl 1 (2004) A185
79. Yang H., Qi X., Das K., et al. In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation rtN236T in the HGV polymerase. [abstract]. J Hepatol 40 Suppl (2004) A383
80. Hussain M.T., Fung S., Sablon E., et al. A sensitive line probe assay to simultaneously detect lamivudine and adefovir resistant mutations. [abstract]. Hepatology 42 Suppl 1 (2005) A969
81. Marcellin P., and Asselah T. Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B. J Hepatol 43 6 (2005) 920-923
82. Fung S.K., Andreone P., Han S.H., et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 43 (2005) 937-943
83. Durantel S., Werle B., Durantel D., et al. Different profiles of response to adefovir dipivoxil and factors that may influence response in patients with chronic hepatitis B. [abstract]. Hepatology 40 S4 (2004) A1132
84. Lok A.S., Fung S.K., Han S., et al. Virologic response and resistance to adefovir therapy in liver transplant patients. [abstract]. Hepatology 42 Suppl 1 (2005) A91
85. Lampertico P., Marzano A., Levrero M., et al. A multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: a 2-year analysis of 604 patients. [abstract]. Hepatology 42 Suppl 1 (2005) 591
86. Lai CL, Rosmawati M, Lau J, F, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-8.
87. Gish R., Chang T.T., de Man R.A., et al. Entecavir results in substantial virologic and biochemical improvement in HBeAg seroconversion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (Study ETV-022). [abstract]. Hepatology 42 Suppl 2 (2005) 267
88. Colonno R., Rose R., Levine S., et al. Entecavir two year resistance update: no resistance observed in nucleoside naïve patients and low frequency resistance in lamivudine refractory patients. [abstract]. Hepatology 42 Suppl 1 (2005) 573
89. Levine S., Hernandez D., Yamanaka G., et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 46 (2002) 2525-2532
90. Chang T.T., Gish R.G., Hadziyannis S.J., et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129 (2005) 1198-1209
91. Colonno R.J., Rose R., Levine S.M., et al. Emergence of entecavir-resistant hepatitis B virus after 1 year of therapy in phase II and II studies is only observed in lamivudine refractory patients. [abstract]. Hepatology 40 Suppl 1 (2005) A1146
92. Tenny D.J., Levine S., Rose R., et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 48 (2004) 3498-3507
93. Perrillo R.P., Hann H.W., Mutimer D., et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 126 (2004) 81-90
94. Peters M., Hann H.W., Martin P., et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126 (2004) 91-101
95. Schiff E., Lai C.L., Neuhaus P., et al. Adefovir dipivoxil provides significant clinical benefit, reduces MELD score and prevents transplantation in chronic hepatitis B patients wait listed for liver transplantation with lamivudine-resistance. [abstract]. J Hepatol 42 S2 (2005) A7
96. Schiff E., Lai C.L., Neuhaus P., et al. Long-term safety and efficacy of adefovir dipivoxil in the treatment of chronic hepatitis B in patients pre and post-liver transplantation with lamivudine resistant hepatitis B virus. [abstract]. Hepatology 42 Suppl 1 (2004) 660
97. Lampertico P., Vigano M., Manenti E., et al. Adefovir rapidly suppresses hepatitis B in HBeAg negative patients developing genotypic resistance to lamivudine. Hepatology 42 (2005) 1414-1419
98. Brunelle M.N., Jacquard A.C., Pichoud C., et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41 (2004) 1391-1398
99. FDA advisory board review of entecavir. Available at: http:www.fda.gov. Accessed March 29, 2005.
100. Van Bommel F., Wunsche T., Mauss S., et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40 (2004) 1421-1425
101. Van Bommel F., Mauss S., Zollner B., et al. Long-term effect of tenofovir in the treatment of lamivudine-resistant hepatitis B virus infections in comparison to adefovir. [abstract]. Hepatology 42 Suppl 1 (2005) A184
102. Van Bommel F., Feucht H.H., Moller B., et al. Tenofovir rescue for patients with lamivudine resistant HBV infection with suboptimal virologic response to adefovir. [abstract]. Hepatology 42 Suppl 1 (2005) A1000
103. Neff G.W., O'Brien C.B., Nery J., et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 10 (2004) 1372-1378
104. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36.
105. Lai C.L., Gane E., Liaw Y.F., et al. Telbivudine versus lamivudine for chronic hepatitis B: first year results from the international Phase III GLOBE trial. [abstract]. Hepatology 42 Suppl 1 (2005) A748
106. Bartholomeusz A., Locarnini S., Ayers A., et al. Mechanistic basis for hepatitis B virus resistance to acyclic nucleoside phosphonate analogues adefovir and tenofovir. [abstract]. Hepatology 42 Suppl 1 (2005) 594
107. Gish R.G., Leung N.W.Y., Wright T.L., et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 46 (2002) 1734-1740
108. Gish R., Leung N., Wang C., et al. Antiviral activity, safety and incidence of resistance in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years. [abstract]. Hepatology 36 (2002) 372
109. Marcellin P, Mommeja-MarinH, Sacks SL, et al. A phase II dose-escalating trail of clevudine in patients with chronic hepatitis B. Hepatology 2004;40:140-8.
110. Yoo B.C., Koh K.C., Chung Y.H., et al. Clevudine is highly efficacious in HBeAg(-) chronic hepatitis B patients with a sustained antiviral effect after cessation of therapy. [abstract]. Hepatology 42 Suppl 1 (2005) A183
111. Yoo B.C., Kim J.H., Lee K.S., et al. A 24-week clevudine monotherapy produced profound on-treatment viral suppression as well as sustained viral suppression and normalization of aminotransferases levels for 24 weeks off-treatment in HBeAg(+) chronic hepatitis B patients. [abstract]. Hepatology 42 Suppl 1 (2005) A186
112. Schuurman R., Nijhuis M., van Leeuwen R., et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 171 (1995) 1411-1419
113. Mutimer D, Pillay D, Cook P, et al. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis 2000;181:713-6.
114. Fontana R.J., and Lok A.S.F. Combination therapy for chronic hepatitis B. Hepatology 26 (1997) 234-238
115. Wursthorn K., Buggisch P., Zoellner B., et al. Combination therapy of PegIFNa2b and adefovir dipivoxil in chronic hepatitis B leads to a strong suppression of cccDNA and high rates of HBe and HBs seroconversion. [abstract]. J Hepatol 42 S2 (2005) A76
116. Lau G.K., Cooksley H., Riberio R.M., et al. Randomized, double-bond study comparing adefovir dipivoxil plus emtricitabine combination therapy versus ADV alone in HBeAg positive chronic hepatitis B: efficacy and mechanisms of treatment response. Hepatology 40 (2004) A1155